Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Device Impact on the Efficacy of Serum Product Study

10 de novembro de 2026 atualizado por: ChinaNorm

The goal of this clinical trial is to learn whether combining a beauty device with the test product affects skin parameters in women troubled by wrinkles. It aims to evaluate the impact of the beauty device on the efficacy of the test product. The main questions it aims to answer are:

- Does the combination of the beauty device plus test product achieve better skin improvement compared with using the test product alone?

Researchers will compare beauty device + test product applied to one half of the face and one side of the neck against the test product alone applied to the contralateral half-face and neck, to see whether the beauty device enhances the efficacy of the test product.

Participants will:

  • Receive randomized split-face and split-neck treatment during the study
  • Attend 10 scheduled study visits
  • Undergo standardized image capture, clinical assessment and instrumental skin measurement

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

35

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recrutamento
        • Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

25 anos a 55 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • 1. Chinese female with 25 - 55 years old.
  • 2. All skin types, 50% self-declare sensitive skin.
  • 3. Self- declare with concerns on facial wrinkle problems.
  • 4. The difference in clinical grading between the two sides of the face should be less than one point.
  • 5. Presenting with following certain degree skin qualities clinical grading by dermatologist: Skin radiance, brightness, global appearance of fine lines, elasticity, plumpness, skin firmness: 3≤grade≤6 (refer to 0-9 scale); Crow's feet wrinkles: 2≤ grade (Skin Aging Atlas); Underneath eye wrinkle: 2≤ grade (Skin Aging Atlas); Nasolabial folds:2 ≤ grade (Skin Aging Atlas); Ptosis of the lower part of the face 1≤grade (Skin Aging Atlas);
  • 6. Did not participate any clinical test or cosmetic product test on skin within 3 months.
  • 7. Did not participate any chemical/beauty procedures for previous 6 months.
  • 8. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
  • 9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
  • 10. Must be willing to comply with all study protocol requirements.

Exclusion Criteria:

  • 1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
  • 2. Subject deprived of rights by a court or administrative order.
  • 3. Major subject to a guardianship order.
  • 4. Subject residing in a health or social care establishment.
  • 5. Patient in an emergency setting.
  • 6. Subject with a skin disease in the test areas as well as skin allergy (particularly e.g., acne, rosacea, eczema).
  • 7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
  • 8. Immuno-compromised subject.
  • 9. Subject with history of allergy to cosmetic or personal care products or ingredients.
  • 10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
  • 11. Subject regularly practicing aquatic or nautical sports.
  • 12. Subject regularly attending a sauna.
  • 13. Subject with physical highly sensitive constitution.
  • 14. Subject with cardiovascular or circulatory history.
  • 15. Subject with a history of skin cancer or malignant melanoma.
  • 16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune- suppressants in the last 6 months before study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm 1

Randomly assigned half-face and half-neck receives the beauty device combined with the test product. The study includes short-term on-site application and long-term home-use regimen.

Short-term: 1.48 g test product applied on half-face & half-neck, massaged by beauty device for about 5 min 50 sec at study site. Long-term: Subjects follow standardized home skincare routine between visits. On-site visits: treatment side receives beauty device and test product.

Comparador Ativo: Arm 2

Contralateral half-face and half-neck receives only the test product without the beauty device, as within-subject control. The same home skincare regimen is followed.

Short-term: 0.45 g test product manually applied on half-face by staff, no beauty device. Long-term: same full-face home skincare routine. On-site visits: only test product is applied on this control side without beauty device treatment.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Dermatologist clinical assessment of skin parameters using modified Griffiths 10-point scale
Prazo: 2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

A dermatologist evaluates skin parameters on the left and right half-face/half-neck separately. Assessments include skin tone, skin quality and wrinkle parameters graded on a 0-9 scale. Half-point (0.5) or incremental values (0.4/0.6) may be used. The rater is blinded to prior scores after baseline.

2 weeks before baseline, Baseline, 1 hour and 24 hours after product application, 1 hour after product application at Week 1 visit, 1 hour after product application at Week 2 visit,1 hour after product application at Week 3 visit and Week 4 visit.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Stratum corneum hydration measured by Corneometer® CM 825
Prazo: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

Skin hydration is measured bilaterally on cheeks using Corneometer® CM 825 (capacitance method). The mean value of 3 consecutive valid readings is recorded; higher values indicate greater hydration.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
Transepidermal water loss (TEWL) measured by Vapometer
Prazo: Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit

TEWL is measured bilaterally on cheeks using Vapometer. One reading is taken per site. Unit: g/m²h; lower values indicate better skin barrier function.

Baseline, Week1 visit, Week2 visit, Week3 visit, Week4 visit
wrinkle analysis using Antera 3D
Prazo: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Antera 3D generates 3D colour images of skin surface by analysing shadow and light reflection. Standard wrinkle photographs are captured and analysed.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Skin texture analysis using VisioScan VC20
Prazo: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

VisioScan VC20 (UV CCD imaging probe) captures skin images on bilateral cheeks and neck. Images are processed and analysed by SELS software to evaluate skin smoothness.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
3D facial imaging using Vectera-H2
Prazo: Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4

Handheld Vectera-H2 captures 180° stereophotogrammetric 3D facial images. Assessment endpoint: facial fullness.

Baseline, 1 hour after product application, Week3 (1 hour after product application at Week3 visit), Week4
Facial imaging acquisition using VISIA®-CR (Canfield)
Prazo: Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Facial images are captured by trained staff with VISIA®-CR, equipped with multiple light sources (standard, cross-polarized, parallel polarized, oblique, UV). Images are taken from left, central and right views with subject wearing hairnet and eyes closed.

Baseline, 1 hour and 24 hours after product application, Week1 (visit and 1h post-application), Week2 (visit and 1h post-application), Week3 (visit and 1h post-application), Week4

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

23 de setembro de 2026

Conclusão Primária (Real)

10 de novembro de 2026

Conclusão do estudo (Estimado)

30 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

16 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • C26005101

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever